Strikingly, the OVV-01-7h treatment group exhibited complete absence of NY-ESO-1 in normal compartments but showed a marked upregulation of NY-ESO-1 expression in the plasma of tumor cells, with strong immunoreactivity (3+ intensity) observed in 30% of tumor cells compared to the vehicle control. This evidence concerns the gene CTAG1B and neoplasm.